France banned several types of textured breast implants Friday as a precautionary measure. The implants are suspected of causing a rare form of cancer.
The San Diego, CA-based company is set eliminate all of its direct sales force and some of its headquarters staff in a move that could reduce operating expenses in 2Q19 by about 35%.
Ethicon's Linx reflux management system reduced medical costs enough that it more than offsets the higher procedure cost compared to a more invasive anti-reflux surgery, according to a study presented at SAGES 2019.
Alcon paid $285 million to acquire PowerVision, a company developing fluid-based intraocular lens implants.
Rani Therapeutics has conducted the first human study of a robotic capsule set to replace injections.
Check-Cap received CE mark for its C-Scan Capsule in January of this year, now the Isfiya, Israel-based company is setting its sights on the U.S. market.
University of Bristol Medical School Researchers led a study that shows cemented metal-on-plastic hip replacements less than 36 mm in diameter are the most cost-effective in patients older than 65.
An industry expert shares how emerging micro and nanotechnologies could shape the next generation of implantable drug-delivery systems.
FDA is alerting doctors and patients about the risk of complications when certain implanted pumps are used to deliver pain medications not approved for use with the devices.
Precise Bio is trying to develop bio-printed eye-related tissues to treat ophthalmic diseases. The company has already transplanted a 3D-printed corneal graft in animals.
A report posted in FDA's MedSun database describes two heart pumps that were returned to the manufacturer for investigation.
The Utah Supreme Court will decide whether to apply to medical devices a key legal doctrine that protects manufacturers of technologically-advanced products from the unfair application of strict liability.
A recently published study links silicone breast implants with a handful of rare diseases, but an FDA expert points to flaws in the study and says it highlights the need for better postmarket evidence generation.
The company's technology has been hailed as the first major change in breast tissue expansion in almost 40 years.